Impact of guideline adherence on the prognosis of Barcelona clinic liver cancer stage B hepatocellular carcinoma

Table 4 Distribution of treatment strategies according to each hepatocellular carcinoma guideline

Treatment strategy	2000 EASL		2012 EASL			2005 AASLD		2010 AASLD		2010 APASL
	Adherence	Upward	Adherence	Upward	Downward	Adherence	Upward	Adherence	Upward	Adherence	Upward	Downward
Total, n (%)	269 (76.2)	77 (21.8)	168 (56.6)	82 (27.6)	47 (15.8)	130 (71.8)	46 (15.5)	287 (61.2)	154 (32.8)	486 (91.7)	22 (4.7)	22 (4.7)
Liver resection	0	56 (72.7)	0	57 (63.4)	0	0	26 (56.5)	0	87 (56.5)	94 (19.3)	0	0
Liver transplantation	0	11 (14.3)	0	4 (4.9)	0	0	6 (13.0)	0	9 (5.8)	0	11 (50)	0
Radiofrequency ablation	0	6 (7.8)	0	7 (8.5)	0	0	4 (8.7)	0	10 (6.5)	0	11 (50)	0
TACE	261 (97)	0	168 (100)	0	0	130 (100)	10 (21.7)	269 (93.7)	45 (28.2)	6	0	0
TACE with drug-eluting beads	0	4 (5.2)	0	10 (12.2)	0	0	0	12 (4.2)	2 (1.3)	14 (2.9)	0	0
Radioembolization (Yttrium-90)	0	0	0	4 (4.9)	0	0	0	0	1 (0.6)	4 (0.8)	0	0
Chemotherapy	8 (1.9)	0	0	0	13 (27.7)	0	0	3 (0.9)	0	0	0	20 (90.7)
Radiation therapy	0	0	0	0	2 (4.3)	0	0	0	0	0	0	0
No treatment	0	0	0	0	0	0	0	0	0	0	0	2 (9.1)

Data are presented as number (%). AASLD: American Association for the Study of Liver Diseases; APASL: Asian Pacific Association for the Study of the Liver; EASL: European Association for the Study of the Liver; HCC: Hepatocellular carcinoma; TACE: Transarterial chemoembolization.